Overview
ISO 10993-7:2008/Amd 1:2019 is an important amendment to the international standard focused on the biological evaluation of medical devices, specifically addressing ethylene oxide (EO) sterilization residuals. Published by the International Organization for Standardization (ISO), this amendment clarifies the applicability of allowable residual limits of EO and its by-product, ethylene chlorohydrin (ECH), for vulnerable patient groups such as neonates and infants. It ensures that EO sterilization processes and residual limits consider the unique risks and exposure levels for these sensitive populations, enhancing patient safety and risk management in medical device sterilization.
Key Topics
- Ethylene oxide sterilization residuals: Focuses on EO and ECH residues left on medical devices post-sterilization.
- Exposure classifications:
- Limited exposure (up to 24 hours)
- Prolonged exposure (exceeding 24 hours, up to 30 days)
- Permanent exposure (exceeding 30 days)
- Allowable limits for EO and ECH: Adjusted limits based on device exposure duration and patient population body mass.
- Special populations: Neonates, infants, children, and premature neonates have specific dose limits based on their lower body mass and sensitivity.
- Concomitant and proportional exposure factors (CEF and PEF): Guidelines for adjusting allowable limits when multiple devices are used or partial exposure is expected.
- Risk management integration: Refers to ISO 10993-1:2018 for overall biological evaluation and testing within a risk management framework.
- Analytical validation: Emphasizes validation of testing methods for EO and ECH residues with references to recognized guidelines such as ICH Q2 (R2).
- Extraction and testing protocols: Specifies procedures for simulating product use and exhaustive extraction for devices with prolonged or permanent contact.
Applications
- Medical device sterilization validation: Assists manufacturers in validating EO sterilization processes and controlling residuals to meet safety standards.
- Regulatory submissions: Supports compliance with regulatory bodies by providing standardized, evidence-based limits for EO and ECH residuals, especially important for devices intended for neonates and infants.
- Product safety evaluation: Enhances the biological risk assessment of medical devices by addressing special patient populations and cumulative exposure scenarios.
- Multi-device systems: Offers guidance for scenarios involving multiple EO-sterilized devices used concurrently, including convenience kits and multi-component assemblies.
- Clinical risk management: Integrates with broader ISO 10993 series standards to support safe medical device design and clinical evaluation.
Related Standards
- ISO 10993-1:2018 – Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process.
- ISO 11135:2014 – Sterilization of health-care products using ethylene oxide; requirements for sterilization process development, validation, and routine control.
- ISO/IEC Directives, Part 1 and Part 2 – Procedures and editorial rules for developing and maintaining ISO standards.
- ICH Q2 (R2) – Validation of analytical procedures, including methods for detecting EO and ECH residues.
- ISO 10993 series – Comprehensive guidance covering the biological evaluation and testing of medical devices including cytotoxicity, sensitization, and toxicological risks.
- ASTM E691-18 – Standard practice for interlaboratory studies relevant to test method precision that may support EO residue analysis.
Keywords: ISO 10993-7 amendment, ethylene oxide residuals, medical device sterilization, EO limits neonates, EO limits infants, biological evaluation medical devices, ethylene chlorohydrin residue, sterilization residual safety, medical device risk management, EO sterilization validation, neonatal medical device safety, ISO biological evaluation standards.